Successful treatment with tigecycline of two patients with complicated urinary tract infections caused by extended-spectrum beta-lactamase-producing Escherichia coli.

摘要

We read with great interest the letter by Nix and Matthias regarding pharmacokinetic considerations relating to tigecycline use in urinary tract infections (UTIs). We agree with the authors that tigecycline should not be used for UTIs when other therapies including aminoglycosides, carbapenems and colistin are options; however, in rare situations, tigecycline may be considered. In a recent study, Rodriguez-Bano et al. demonstrated that the susceptibility of all extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli to tigecycline was 100%. Since ESBL-producing E. coli is an increasing cause of community-onset bloodstream infections, they suggested that tigecycline might be an alternative in the treatment of non-UTIs. Here, we describe two patients with complicated UTIs caused by ESBL-producing E. coli, who were successfully treated with tigecycline.